Vismodegib effectively treats advanced basal cell carcinoma but requires careful management of serious side effects.
16 citations
,
March 2020 in “Journal of The American Academy of Dermatology” Oral bicalutamide is safe and effective for female hair loss.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
9 citations
,
October 2021 in “International Journal of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
1 citations
,
January 2019 in “Skin Pharmacology and Physiology” Eplerenone, a mineralocorticoid receptor antagonist, was found to promote hair growth in human hair follicles.
11 citations
,
November 2019 in “Clinical Case Reports” A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
December 2025 in “The Journal of Dermatology” Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
25 citations
,
April 2010 in “Clinical and Experimental Dermatology” Erlotinib can cause hair loss and scalp issues, which improve after stopping the drug.
November 2024 in “Journal of the European Academy of Dermatology and Venereology” Long-term baricitinib treatment can lead to significant scalp hair regrowth in patients initially showing only eyebrow or eyelash regrowth.
6 citations
,
June 2021 in “EClinicalMedicine” ALRV5XR significantly improves hair density in women with hair loss and is well-tolerated.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” EX104 effectively promotes hair growth and regenerates follicles in androgenetic alopecia.
October 2018 in “Annals of oncology” Topical calcitriol (BPM31543) is safe for preventing hair loss from chemotherapy and shows some effectiveness.
November 2025 in “Journal of Investigative Dermatology” IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.
65 citations
,
February 2015 in “Neuro-Oncology” Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
January 2018 in “Figshare” Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
August 2025 in “Journal of the American Academy of Dermatology”
3 citations
,
June 2023 in “Journal of cosmetic dermatology” A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
34 citations
,
February 1993 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Certain 4-azasteroids are effective at blocking the enzyme that processes testosterone in human skin and could help treat acne, excessive hair growth, and male pattern baldness.
June 2025 in “Theranostics” Rapamycin-primed exosomes can significantly boost hair regrowth.
37 citations
,
September 2018 in “Journal of the American Academy of Dermatology” Ruxolitinib can help regrow hair in severe alopecia areata.
December 2025 in “Chemical Engineering Journal”
April 2023 in “Journal of Investigative Dermatology” ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.
January 2024 in “Acta dermato-venereologica”
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
12 citations
,
December 1987 in “Cancer Chemotherapy and Pharmacology” Vitamin E in the diet might help protect against hair loss caused by the chemotherapy drug doxorubicin in rabbits.
November 2025 in “Journal of Investigative Dermatology” 15 citations
,
May 1987 in “Fundamental and applied toxicology” SMR-2 and SMR-6 are much more toxic than retinoic acid, causing severe side effects.
October 2023 in “The Open Dermatology Journal” Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.
2 citations
,
March 2018 in “Current Opinion in Urology” 5-alpha reductase inhibitors can cause sexual, neurologic, endocrine, and cardiovascular side effects, but these are rare and usually stop after ending treatment.
3 citations
,
September 2016 in “Dermatologic Therapy” Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.